KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

Nikolaj Frost, Jens Kollmeier, Claudia Vollbrecht, Christian Grah, Burkhard Matthes, Dennis Pultermann, Maximilian von Laffert, Heike Lüders, Elisabeth Olive, Matthias Raspe, Thomas Mairinger, Sebastian Ochsenreither, Torsten Blum, Michael Hummel, Norbert Suttorp, Martin Witzenrath, Christian Grohé